7 news items
Atossa Therapeutics Announces Support Of New Breast Cancer Screening Guidelines
ATOS
7 May 24
in detecting cancerous lesions. Atossa Therapeutics recognizes the significance of these improved guidelines in empowering both healthcare providers
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response
ARVN
ATOS
ICCM
30 Apr 24
the FDA's response. Driven by favorable healthcare economics combined with patient satisfaction and demand, we expect rapid adoption pending
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response
ARVN
ATOS
ICCM
30 Apr 24
the FDA's response. Driven by favorable healthcare economics combined with patient satisfaction and demand, we expect rapid adoption
Atossa Therapeutics And Quantum Leap Healthcare Initiates I-SPY 2 Clinical Trial To Evaluate (Z)-Endoxifen In Combination With Abemaciclib In Women With ER+/HER2- Breast Cancer
ATOS
15 Apr 24
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
ATOS
15 Apr 24
" or the "Company") and Quantum Leap Healthcare Collaborative™ today announced the initiation of a new study to evaluate Atossa's proprietary (Z)-endoxifen
ab813ib3
ATOS
11 Apr 24
" or the "Company") today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare
u1b5zxggt7syoaedlbu80bkh8
ATOS
22 Feb 24
and operated by Quantum Leap Healthcare Collaborative, which was established in 2005 as a collaboration between medical researchers at University of California
- Prev
- 1
- Next